This dual effect, upregulation of PD-L1/PD-L2 and enhancement of inflammatory TME characteristics, can sensitize tumors in various contexts, such as melanoma and non-small cell lung cancer, rendering them more responsive to PD-1/PD-L1 blockade therapy [198, 199]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.